Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury

Oligonucleotides

Volumn 14, Issue 4, 2004, Pages 299-310

  Masarjian, Lilit ^a,b   De Peyster, Ann ^a   Levin, Arthur A ^b   Monteith, David K ^b,c  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ISIS 3521; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY THY 1; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GEL ELECTROPHORESIS; GLOMERULUS; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

EID: 12444287964     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2004.14.299     Document Type: Article

References (47)

1. AGRAWAL, S., TEMSAMANI, J., and TANG, J.Y. (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599.
2. AKHTAR, S., BECK, G.F., HAWLEY, P., IRWIN, W.J., and GIBSON, I. (1996). The influence of polarized epithelial (Caco-2) cell differentiation on the cellular binding of phosphodiester and phosphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev. 6, 197-206.
3. ANDRADE, M., SCOZZARI, A., COLE, D.L., and RAVIJUMAR, V.T. (1994). Efficient synthesis of antisense oligodeoxyribonucleotide phosphorothioates. Bioorg. Med. Chem. Lett. 4, 2017-2022,
4. BAGCHUS, W.M., HOEDEMAEKER, P.J., ROZING, J., and BAKKER, W.W. (1986). Glomerulonephritis induces by monoclonal anti-Thy 1.1 antibodies. Lab. Invest. 55, 680-687.
5. BECK, G.F., IRWIN, W.J., NICKLIN, P.L., and AKHTAR, S. (1996). Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial Caco-2 cells. Pharm. Res. 13, 1028-1037.
6. BIJSTERBOSCH, M.K., MANOHARAN, M., RUMP, E.T., DE VRUEH, R.L.A., VAN VEGHEL, R., TIVAL, K.L., BIESSEN, E.A.L., BENNETT, F.C., COOK, D.P., and T.J. van Berkel. (1997). In vivo fate of phosphorothioate antisense oligodeoxynucleotides: Predominant uptake by scavenger receptors on endothelial cells, Nucleic Acids Res. 25, 3290-3296.
7. BROWN, D.A., KANG, S.H., GRYAZNOV, S.M., DEDIONISIO, L., HEIDENREICH, O., SULLIVAN, S., XU, X., and NERENBERG, M.I. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805.
8. BUTLER, M., CROOKE, R.M., GRAHAM, M.J., LEMONIDIS, K.M., LOUGHEED, M., MURRAY, S.F., WITCHELL, D., STEINBRECHER, U., and BENNETT, C.F. (2000). Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. J. Pharmacol. Exp. Ther. 292, 489-496.
9. BUTLER, M., STECKER, K., and BENNETT, C.F. (1997a). Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77, 379-388.
10. BUTLER, M., STECKER, K., and BENNETT, C.F. (1997b). Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Nucleosides Nucleotides 16, 1761-1764.
11. CHAUDHURI, G. (1997). Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite. Biochem. Pharmacol. 53, 385-391.
12. CLARK, C.T., and SCHKADE, L.W. (1979).Statistical Analysis for Administrative Decisions. (South-Western Publishing Co., Cincinnati, OH).
13. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190.
14. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269, 89-94.
15. CROOKE, R.M. (1993a). Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methylphosphonate oligonucleotides. In: Antisense Research and Applications. S.T. Crooke, B. Lebleu, eds. (CRC Press, Boca Raton, FL), pp. 427-449.
16. CROOKE, R.M. (1993b). In vitro and in vivo toxicology of first-generation analogs. In: Antisense Research and Applications. S.T. Crooke, B. Lebleu, eds. (CRC Press, Boca Raton, FL), pp. 471-491.
17. CROOKE, R.M., GRAHAM, M.J., COOKE, M.E., and CROOKE, S.T. (1995). In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275, 462-473.
18. CROOKE, S.T. (1991). Antisense technology. Curr. Opin. Biotechnol. 2, 282-287.
19. CROOKE, S.T. (1996). Antisense therapeutics. In: Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s. A.C. Cuello, B. Collier, eds. (Birkhauser Verlag, Basel, Switzerland), pp. 393-399.
20. CROOKE, S.T. (1998). Antisense therapeutics. Biotechnol. Gen. Eng. Rev. 15, 121-157.
21. DAUGAARD, G., and ABILDGAARD, U. (1989). Cisplatin nephrotoxicity. Cancer Chemother. Pharmacol. 25, 1-9.
22. DEAN, N.M., CONDON, T.P., MCKAY, R., and BENNETT, C.F. (1994). Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269, 16416-16424.
23. DEAN, N.M., and MCKAY, R. (1994). Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91, 11762-11766.
24. GEARY, R.S., LEEDS, J.M., FITCHETT, J., BURCKIN, T., TROUNG, L., SPAINHOUR, C., CREEK, M., and LEVIN, A.A. (1997a). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25, 1272-1281.
25. GEARY, R.S., LEEDS, J.M., HENRY, S.P., GLOVER, J., SHANAHAN, W., FITCHETT, J., BURCKIN, T., TROUNG, L., and LEVIN, A.A. (1997b). Pharmacokinetic properties of phosphorothioate oligonucleotides. Nucleosides Nucleotides 16, 1689-1693.
26. GEARY, R.S., LEEDS, J.M., HENRY, S.P., MONTEITH, D.K., and LEVIN, A.A. (1997c). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 12, 383-393.
27. IVERSEN, P.L., ZHU, S., MEYER, A., and ZON, G. (1992). Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res. Dev. 2, 211-222.
28. LEE, Y.-S., DLUGOSZ, A.A., MCKAY, R., DEAN, N.M., and YUSPA, S.H. (1997). Definition by specific antisense oligonucleotides of a role for protein kinase C.alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes. Mol. Carcinogenesis 18, 44-53.
29. LEEDS, J.M., GRAHAM, M.J., TROUNG, L., and CUMMINS, L.L. (1996). Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem. 235, 36-43.
30. LEVIN, A.A., GEARY, R.S., LEEDS, J.M., MONTEITH, D.K., YU, R.Z., TEMPLIN, M.V., and HENRY, S.P. (1998a). The pharmacokinetics and toxicity of phosphorothioate oligonucleotides. In: Biotechnology and Safety Assessment. J.A. Thomas, ed. (Taylor & Francis, Philadelphia, PA), 1, 151-175.
31. LEVIN, A.A., MONTEITH, D.K., LEEDS, J.M., NICKLIN, P.L., GEARY, R.S., BUTLER, M., TEMPLIN, M.V., and HENRY, S.P. (1998b). Toxicity of oligodeoxynucleotide therapeutic agents. In: Antisense Research and Application. S.T. Crooke, ed. (Springer, Berlin), 131, 169-215.
32. LI, B., HUGHES, J.A., and PHILLIPS, M.I. (1997). Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem. Int. 31, 393-403.
33. MONTEITH, D.K., GEARY, R.S., JOHNSTON, J., MONIA, B.P., and LEVIN, A.A. (1998). Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci. 46, 365-375.
34. MONTEITH, D.K., HORNER, M.J., GILLETT, N.A., BUTLER, M., GEARY, R.S., BURCKIN, T., WATANABE, T., and LEVIN, A.A. (1999). Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotides in monkeys. Toxicol. Pathol. 27, 307-317.
35. NAKAYAMA, H., OITE, T., KAWACHI, H., MORIOKA, T., KOBAYASHI, H., ORIKASA, M., ARAKAWA, M., and SHIMIZU, F. (1998). Comparative nephritogenicity of two monoclonal antibodies that recognize different epitopes of rat Thy-1.1 molecule. Nephron 78, 453-463.
36. NICKLIN, P.L., CRAIG, S.J., and PHILLIPS, J.A. (1998). Pharmacokinetic properties of phosphorothioates in animals-Absorption, distribution, metabolism and elimination. In: Antisense Research and Applications. S.T. Crooke, ed. (Springer-Verlag, Berlin), 131, 141-168.
37. OBERBAUER, R., SCHREINER, G.F., and MEYER, T.W. (1995). Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int. 48, 1226-1232.
38. PAUL, L.C., RENNKE, H.G., MILFORD, E.L., and CARPENTER, C.B. (1984). Thy-1.1 in glomeruli of rat kidneys. Kidney Int. 25, 771-777.
39. PHILLIPS, J.A., CRAIG, S.J., BAYLEY, D., CHRISTIAN, R.A., GEARY, R.S., and NICKLIN, P.L. (1997). Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54, 657-668.
40. PLENAT, F., KLEIN-MONHOVEN, N., MARIE, B., VIGNAUD, J.-M., and DUPREZ, A. (1995). Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. Am. J. Pathol. 147, 124-135.
41. RAPPAPORT, J., HANSS, B., KOPP, J.B., COPELAND, T.D., BRUGGEMAN, L.A., COFFMAN, T.M., and KLOTMAN, P.E. (1995). Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int. 47, 1462-1469.
42. RIFAI, A., BYRSCH, W., FADDEN, K., CLARK, J., and SCHLINGENSIPEN, K.-H. (1996). Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am. J. Pathol. 1419, 717-725.
43. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45, 932-943.
44. SAWAI, K., TAKENORI, M., TAKAKURA, Y., and HASHIDA, M. (1995). Renal disposition characteristics of oligonucleotides modified at terminal linkages in perfused rat kidney. Antisense Res. Dev. 5, 279-287.
45. SRIVATSA, S.G., BATT, M., SCHUETTE, J., CARLSON, R.H., FITCHETT, J., LEE, C., and COLE, D.L. (1994). Quantitative capillary gel electrophoresis assay of phosphorothioate oligonucleotides in pharmaceutical formulations. J. Chromatogr. 680, 469-477.
46. STEWARD, A., CHRISTIAN, R.A., HAMILTON, K.O., and NICKLIN, P.L. (1998). Co-administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): A role for the scavenger receptor in its in vivo disposition. Biochem. Pharmacol. 56, 509-516.
47. YU, R.Z., GEARY, R.S., LEEDS, J.M., USHIRO-WATANABE, T., MOORE, M., FITCHETT, J., MATSON, J., BURCKIN, T., TEMPLIN, M.V., and LEVIN, A.A. (2001). Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci. 90, 182-193.